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The reactivity of 1-alkyl-2-(bromomethyl)aziridines with respect to different types of oxygen-, 
nitrogen- and sulphur-centered nucleophiles has been evaluated, pointing to the conclusion that 
these substrates can be applied successfully as synthetic equivalents for the aziridinylmethyl 
cation synthon towards the corresponding 2-[(heteroatom)methyl]aziridines in good yields. 
 







Aziridines have proven to be excellent building blocks for the synthesis of a large variety of ring 
opened and ring expanded amines due to the inherent reactivity of the constrained ring.1 2-
(Halomethyl)aziridines comprise a remarkable class of aziridine derivatives with diverse 
synthetic applications. In former communications, we have demonstrated that activated 1-
arenesulfonyl-2-(bromomethyl)aziridines 1 can be applied successfully as synthetic equivalents 
for the 2-aminopropane dication synthon 2 (Figure 1) towards α-branched N-tosylamides upon 
treatment with either carbon-centered2 or heteroatom-centered3 nucleophiles. Their non-activated 
counterparts, 1-alkyl-2-(bromomethyl)aziridines 3,4 comprise a mainly unexplored class of 
functionalized aziridine derivatives. Previously, we reported the successful coupling of 1-
alkylaziridines 3 with carbon-centered nucleophiles (organocuprates) as a useful method for the 
synthesis of 1,2-dialkylaziridines, pointing to the observation that 1-alkyl-2-
(bromomethyl)aziridines 3 are suitable equivalents for the aziridinylmethyl cation 4 (Figure 1).5 
Contrary to the above-mentioned N-activated 1-arenesulfonylaziridines, the focus lies on the 
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absence of ring opening in order to develop a convenient method for aziridine synthesis. In the 
present report, the aziridinylmethyl cation equivalency of 1-alkyl-2-(bromomethyl)aziridines 3 
will be further elaborated extensively utilizing different heteroatom-centered nucleophiles 
instead of carbon nucleophiles, affording a suitable approach towards 1-alkyl-2-

















Results and Discussion 
 
1-Alkyl-2-(bromomethyl)aziridines 3 can easily be prepared in a three-step procedure starting 
from the appropriate aldehydes.4 Subsequently, these aziridines 3 were treated with a variety of 
oxygen, nitrogen and sulphur nucleophiles to afford the corresponding 2-
[(heteroatom)methyl]aziridines. As demonstrated before, the substitution of the bromo atom in 1-
alkyl-2-(bromomethyl)aziridines 3 by a nucleophile takes place via a direct attack at the 
halogenated carbon atom (instead of ring opening and subsequent ring closure which occurs 
when N-activated 2-(bromomethyl)aziridines 1 are used),6 which is of significance whenever 
asymmetric synthesis towards chiral targets compounds is contemplated, e.g. starting from chiral 
substrates 3.7
For the synthesis of 2-(oxymethyl)aziridines, three different types of oxygen-centered 
nucleophiles were evaluated successfully, i.e. alkoxides, aryloxides and carboxylates. 1-Alkyl-2-
(bromomethyl)aziridines 3 can be easily transformed into the corresponding 2-
(alkoxymethyl)aziridines 5 upon treatment with 1.2 – 3 equiv of sodium alkoxides in alcohol at 
room temperature or reflux for 1 to 2 hours (Scheme 1, Table 1). This has resulted in the 
synthesis of 2-(methoxymethyl)aziridines 5a,c,e,f, 2-(ethoxymethyl)aziridine 5b, 2-
(isopropoxymethyl)aziridine 5d and 2-(allyloxymethyl)aziridine 5g. This methodology offers an 
easy and efficient alternative for the procedure developed by Deyrup, in which alcoholic sodium 
hydroxide (1N) was used for the treatment of 2-(tosyloxymethyl)aziridines upon a prolonged 
reaction time (2 days).8 Several other 2-(allyloxymethyl)aziridines have been prepared and used 
previously for the diastereoselective synthesis of cis-3,5-disubstituted morpholine derivatives 
upon treatment with bromine in dichloromethane.9 2-(tert-Butoxymethyl)-1-neopentylaziridine 
5h was prepared in a different way, involving the treatment of 2-(bromomethyl)-1-
neopentylaziridine with 2 equiv of KOtBu in refluxing THF for 1 hour (Table 1, entry 8). 
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The incorporation of an aryloxy moiety, which is often required for biological activity,10 can 
be very efficiently established by means of a nucleophilic substitution of the bromo atom of the 
aziridines 3 using a phenolate anion as a nucleophile. As reported before, treatment of aziridines 
3 with 2.2 equivalents of phenol or, alternatively, a substituted bromo- or chlorophenol, and 5 
equivalents of K2CO3 in a mixture of DMF and acetone (1/1) afforded the corresponding 2-
(aryloxymethyl)aziridines 6 in excellent yields and high purity after reflux for 10 to 20 hours 
(Scheme 1).11 The latter aziridines have been used successfully for the synthesis of biologically 
relevant 2-amino-1-aryloxy-3-methoxypropanes.11 Known methods for the synthesis of 2-
(aryloxymethyl)aziridines are usually more cumbrous and start from the corresponding 2-
(aryloxymethyl)oxiranes12 or from acyclic β-amino alcohols,13 or involve the addition of 
ethoxycarbonylnitrene and the ethoxycarbonylnitrenium ion to allylic ethers.14
Alternatively, the potassium salts of two different carboxylic acids were used as oxygen 
nucleophiles to accomplish the nucleophilic displacement of the bromo atom in aziridines 3. 
Thus, 1-arylmethyl-2-(bromomethyl)aziridines 3 were converted into the corresponding 2-
(alkanoyloxymethyl)aziridines 7 upon treatment with 1 equiv of potassium 2-methylpropanoate 
or potassium 2-methylbutyrate in DMSO in excellent yields after heating at 80°C for 15 hours 
(Scheme 1, Table 2). In the case of 2-methylbutyrate 7d, the two diastereomers (ratio 53/47) 
appeared to be inseparable by chromatography (GC and flash).15 For example, 2-
(alkanoyloxymethyl)aziridines 7 can be used for the synthesis of functionalized β-fluoro 
amines,15 which are of interest in medicinal chemistry.16 2-(Alkanoyloxymethyl)aziridines, 
mainly 2-(acetoxymethyl)aziridines, have been prepared in other (longer) ways, usually by 
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Table 1. Synthesis of 2-(alkoxymethyl)aziridines 5 from 2-(bromomethyl)aziridines 3 (Scheme 1) 
Entry R R’ Conditions 
Compound 5
(Yield) 
1 C6H5 Me 1.2 equiv NaOMe/MeOH (2N), r.t., 2 h 5a (93%) 
2 C6H5 Et 1.2 equiv NaOEt/EtOH (2N), r.t., 2 h 5b (81%) 
3 n-Pr Me 1.2 equiv NaOMe/MeOH (2N), r.t., 2 h 5c (92%) 
4 C6H5 iPr 1.5 equiv NaOiPr/iPrOH (1N), ∆, 1 h 5d (73%) 
5 C(Me)2CH2C6H5 Me 1.5 equiv NaOMe/MeOH (2N), ∆, 1 h 5e (96%) 
6 tBu Me 3 equiv NaOMe/MeOH (2N), ∆, 1.5 h 5f (72%) 
7 4-ClC6H4 Allyl 2.1 equiv NaOCH2CH=CH2/allyl alcohol, ∆, 2 h 5g (95%) 
8 tBu tBu 2 equiv KOtBu, THF, ∆, 1 h 5h (75%) 
 
Table 2. Synthesis of 2-(alkanoyloxymethyl)aziridines 7 from 2-(bromomethyl)aziridines 315 
(Scheme 1) 
Entry R R’ Compound 7 (Yield)
1 3-MeC6H4 H 7a (85%) 
2 2-ClC6H4 H 7b (82%) 
3 4-MeC6H4 H 7c (86%) 
4 C6H5 Me 7d (77%) 
 
Furthermore, also nitrogen-centered nucleophiles have been evaluated to broaden the 
aziridinylmethyl cation equivalency of 1-alkyl-2-(bromomethyl)aziridines 3. 1H-[1,2,4]Triazole 
and 1H-imidazole were used in a large excess (5 equiv) in refluxing acetonitrile for 2.5 days in 
the presence of 4 equiv of potassium carbonate to afford the corresponding novel 2-[(1,2,4-
triazol-1-yl)methyl]aziridines 8 and 2-[(imidazol-1-yl)methyl]aziridines 9 (Scheme 2, Table 3). 
An analogous substitution of 1-[(dialkoxyphosphoryl)methyl]-2-(bromomethyl)aziridines by 
cytosine, thymine, acetylguanine and adenine has been reported, affording 2-substituted 
aziridines as precursors for the corresponding nucleoside phosphonates as potential biologically 
active compounds.19
Also lithium amides were employed, and treatment of 2-(bromomethyl)aziridines 3 with 1 
equiv of a lithium amide in THF or Et2O for 18 to 20 hours at room temperature under nitrogen 
atmosphere furnished the desired 2-(aminomethyl)aziridines 10 (Scheme 2, Table 4). Only very 
few examples of 2-(N-allylaminomethyl)aziridines can be found in the literature.20,21 2-
(Aminomethyl)aziridines are valuable compounds in medicinal chemistry due to the known anti-
tumor activity of platinum complexes of such type of compounds,22 and they can be used as 
substrates for the synthesis of biologically relevant diaminopropane derivatives by ring opening 
reactions.23
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Table 3. Synthesis of 2-[(1,2,4-triazol-1-yl)methyl]aziridines 8 and 2-[(imidazol-1-yl)methyl] 
aziridines 9 from 2-(bromomethyl)aziridines 3 (Scheme 2) 
Entry R Compound 8 or 9 (Yield)
1 C6H5 8a (40%) 
2 4-ClC6H4 8b (40%) 
3 C6H5 9a (60%) 
4 4-ClC6H4 9b (75%) 
 
Table 4. Synthesis of 2-(aminomethyl)aziridines 10 from 2-(bromomethyl)aziridines 3 (Scheme 2) 
Entry R R’ R’’ Compound 10 (Yield)
1 iPr iPr CH=CH2 10a (40%) 
2 tBu tBu CH=CH2 10b (22%) 
3 iPr Me Me 10c (92%) 
4 tBu tBu Me 10d (55%) 
 
Finally, two different sulphur-centered nucleophiles were tested for the substitution of the 
bromo atom in 2-(bromomethyl)aziridines 3. Sodium isopropylthiolate and sodium allylthiolate 
(2 equiv) were used successfully in methanol at room temperature to afford 2-
[(alkylsulfanyl)methyl]aziridines 11 in an efficient approach (Scheme 3, Table 5). Chiral 2-
[(alkylsulfanyl)methyl]aziridines, prepared from acyclic 3-alkylsulfanyl-2-aminopropan-1-ols, 
have been reported to be excellent catalysts for the enantioselective addition of diethylzinc to 
aldehydes24 and for the palladium-catalyzed asymmetric allylic alkylation of 1,3-diphenyl-2-
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propenyl acetate with the dimethymalonate anion.25 Furthermore, a chiral 2-
















Table 5. Synthesis of 2-[(alkylsulfanyl)methyl]aziridines 11 from 2-(bromomethyl)aziridines 3 
(Scheme 3) 
Entry R R’ Compound 11 (Yield)
1 4-ClC6H4 iPr 11a (84%) 
2 4-ClC6H4 allyl 11b (60%) 
 
Treatment of 2-(bromomethyl)aziridines 3 with 2 equivalents of the ambident nucleophile 
potassium thiocyanate has been reported previously to afford the corresponding 2-
(thiocyanomethyl)aziridines in excellent yields after heating for 20 hours at 70°C in DMF.27 The 
latter 2-(thiocyanomethyl)aziridines have been used for the synthesis of 2-iminothiazolidines via 
an intramolecular cyclisation reaction due to the presence of an electrophilic centre in δ-position 
with regard to the nucleophilic nitrogen atom. 
In conclusion, 1-alkyl-2-(bromomethyl)aziridines are excellent synthetic equivalents for the 
aziridinylmethyl cation, providing an easy access to 1-alkyl-2-[(heteroatom)methyl]aziridines 
upon treatment with oxygen-, nitrogen- or sulphur-centered nucleophiles. As 1-alkyl-2-
(bromomethyl)aziridines are considerably less reactive than the corresponding 1-
(arenesulfonyl)aziridines, they are ideally suited for the synthesis of 2-substituted aziridine 
derivatives. In contrast with 1-arenesulfonyl-2-[(heteroatom)methyl]aziridines, the aziridine ring 
of 1-alkyl-2-[(heteroatom)methyl]aziridines is not susceptible to ring opening upon treatment 





Synthesis of 2-(alkoxymethyl)aziridines 5. General procedure 
2-(Bromomethyl)aziridine 3 (15 mmol) was dissolved in a solution of sodium alkoxide in the 
corresponding alcohol (1 - 2N, 1.2 - 3 equiv) and the mixture was stirred for 2 hours at room 
temperature or heated under reflux for 1 - 2 hours. Extraction with dichloromethane, drying 
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(MgSO4), filtration of the drying agent and removal of the solvent in vacuo afforded the 
corresponding 2-(alkoxymethyl)aziridine 5, which can be purified by distillation. 
 
1-Benzyl-2-(methoxymethyl)aziridine (5a). Yield 93%. Colorless oil. 1H NMR (60 MHz, 
CCl4): δ 1.1-1.8 (3H, m, NCH2CH); 3.1-3.6 (2H, m, OCH2); 3.28 (3H, s, OCH3); 3.29 and 3.51 
(2H, 2×d, J=14 Hz, NCH2Ar); 7.33 (5H, s, C6H5). 13C NMR (68 MHz, CDCl3): δ 31.27 
(NCH2CH); 38.36 (NCH); 58.47 (OCH3); 64.24 (NCH2Ar); 74.48 (OCH2); 126.96 
(NCH2HCpara); 128.01 and 128.24 (NCH2HCorthoHCmeta); 139.03 (Carom,quat). IR (NaCl, cm-1): ν = 
1498, 1456, 1347, 1164, 1109. MS (70 eV) m/z (%): 177 (M+, 5); 147 (21); 146 (21); 91 (100); 
86 (75); 65 (18); 56 (69), 45 (69). Purity (GC) > 97%. Anal. Calcd for C11H15NO: C 74.54, H 
8.53, N 7.90. Found: C 74.71, H 8.68, N 7.77. 
1-Benzyl-2-(ethoxymethyl)aziridine (5b). Yield 81%. Colorless oil. Bp. 45-48°C/0.04 mmHg. 
1H NMR (60 MHz, CCl4): δ 1.1-1.9 (3H, m, NCH2CH); 1.12 (3H, t, J=7.0 Hz, CH3); 3.0-3.6 
(6H, m, NCH2Ar and CH2OCH2); 7.28 (5H, s, C6H5). 13C NMR (68 MHz, CDCl3): δ 15.17 
(CH3); 31.71 (NCH2CH); 38.61 (NCH); 64.37 (NCH2Ar); 66.30 (OCH2Me); 72.73 (OCH2CHN); 
127.02 (NCH2HCpara); 128.05 and 128.31 (NCH2HCorthoHCmeta); 139.04 (Carom,quat). IR (NaCl, 
cm-1): ν = 1496, 1456, 1338, 1163, 1110. MS (70 eV) m/z (%): 191 (M+, 1); 147 (10); 146 (16); 
91 (97); 72 (25); 65 (23); 56 (100). Anal. Calcd for C12H17NO: C 75.35, H 8.96, N 7.32. Found: 
C 75.47, H 9.13, N 7.54. 
2-(Methoxymethyl)-1-propylaziridine (5c). Yield 92%. Colorless oil. 1H NMR (60 MHz, 
CDCl3): δ 0.93 (3H, ~t, CH3); 1.1-2.5 (9H, m, (CH2)3NCH2CH); 3.3-3.6 (2H, m, CH2O); 3.45 
(3H, s, OCH3). 13C NMR (68 MHz, CDCl3): δ 14.08 (CH3); 20.54 (CH2CH3); 31.34 and 31.93 
(NCH2CH and NCH2CH2); 37.98 (NCH); 58.84 (0CH3); 61.01 (NCH2Pr); 74.92 (CH2OCH3). IR 
(NaCl, cm-1): ν = 1460, 1347, 1168, 1114. MS (70 eV) m/z (%): 143 (M+, 3); 100 (25); 98 (53); 
86 (13); 70 (100); 58 (12); 57 (21); 58 (12); 57 (21); 56 (35); 55 (12); 45 (41). Purity (GC) > 
97%. Anal. Calcd for C8H17NO: C 67.09, H 11.96, N 9.78. Found: C 67.22, H 12.11, N 9.88. 
1-Benzyl-2-(isopropoxymethyl)aziridine (5d). Yield 73%. Colorless oil. Bp. 88-96°C/0.4 
mmHg. 1H NMR (270 MHz, CDCl3): δ 1.12 (6H, d, J=6.3 Hz, (CH3)2CH); 1.45 (1H, d, J=6.6 
Hz, N(HcisCH)CH); 1.70 (1H, d, J=3.6 Hz, N(HCHtrans)CH); 1.72-1.80 (1H, m, NCH2CH); 3.37-
3.43 (2H, m, CH2O); 3.45 (2H, s, NCH2Ar); 3.53-3.62 (1H, m, CHO); 7.22-7.38 (5H, m, C6H5). 
13C NMR (68 MHz, CDCl3): δ 21.80 and 22.28 ((CH3)2CH); 31.86 (NCH2CH); 39.01 (NCH); 
64.33 (NCH2Ar); 70.35 (OCH2); 71.46 (CHO); 126.97 (NCH2HCpara); 127.99 and 128.28 
(NCH2HCorthoHCmeta); 139.08 (Carom,quat). IR (NaCl, cm-1): ν = 2966, 1497, 1454, 1380, 1370, 
1327, 1160, 1130, 1075, 1028. MS (70 eV) m/z (%): no M+; 162 (M+-43); 146 (22); 132 (11); 91 
(100); 72 (25); 65 (13); 56 (33). Anal. Calcd for C13H19NO: C 76.06, H 9.33, N 6.82. Found: C 
76.26, H 9.50, N 6.68. 
1-(2,2-Dimethyl-3-phenylpropyl)-2-(methoxymethyl)aziridine (5e). Yield 96%. Colorless oil. 
1H NMR (60 MHz, CDCl3): δ 0.90 (6H, s, 2×CH3); 1.1-1.7 (3H, m, NCH2CH); 2.04 and 2.66 
(2×2H, 2×s, NCH2C(Me)2CH2Ar); 3.2-3.4 (2H, m, OCH2); 3.36 (3H, s, OCH3); 7.26 (5H, s, 
C6H5). 13C NMR (68 MHz, CDCl3): δ 25.66 and 25.75 (2×CH3); 32.11 (CH2CHN); 36.41 
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(C(Me)2); 38.35 (CHN); 46.61 (CH2Ar); 58.62 (OCH3); 71.60 (OCH2); 75.04 (NCH2C); 125.73 
(HCpara); 127.56 and 130.67 (HCortho and HCmeta); 139.10 (Carom,quat). IR (NaCl, cm-1): νOMe = 
2820; νaz = 3025. MS (70 eV) m/z (%): 233 (M+, 14); 188 (8); 146 (6); 131 (9); 100 (56); 91 
(28); 71 (12); 70 (40); 56 (8); 55 (8); 45 (16); 42 (100). Purity (GC) > 97%. Anal. Calcd for 
C15H23NO: C 77.21, H 9.93, N 6.00. Found: C 77.34, H 10.09, N 5.88. 
1-Neopentyl-2-(methoxymethyl)aziridine (5f). Yield 72%. Colorless oil. 1H NMR (CDCl3, 60 
MHz): δ 0.97 (9H, s, (CH3)3C); 1.2-1.7 (3H, m, CH2CHN); 1.98 and 2.14 (2H, 2×d, J=11.0 Hz, 
N(HCH)tBu); 3.38 (3H, s, OCH3); 3.2-3.4 (2H, m, OCH2). 13C NMR (CDCl3, 68 MHz): δ 25.59 
((CH3)3C); 29.17 (CH2CHN); 30.02 ((CH3)3C); 35.88 (CHN); 56.08 (CH3O); 71.10 (CH2O); 
72.41 (NCH2tBu). IR (NaCl, cm-1): νOMe = 2820; νaz = 3040. MS (70 eV) m/z (%): 157 (M+, 1); 
112 (7); 100 (21); 71 (7); 70 (22); 57 (6); 56 (7); 55 (6); 45 (21); 43 (15); 42 (100); 41 (21). 
Purity (GC) > 97%. Anal. Calcd for C9H19NO: C 68.74, H 12.18, N 8.91. Found: C 68.91, H 
12.37, N 8.78. 
1-[(4-Chlorophenyl)methyl]-2-[(propenyloxy)methyl]aziridine (5g). Yield 95%. Light-yellow 
oil. Filtration through a pad of silica (Hexane/EtOAc 5/4). 1H NMR (270 MHz, CDCl3): δ 1.45 
(1H, d, J=6.2 Hz, N(HcisCH)CH); 1.73 (1H, d, J=3.6 Hz, N(HCHtrans)CH); 1.77-1.85 (1H, m, 
NCH); 3.35 and 3.50 (2H, 2×d×d, J=10.6, 6.6, 4.3 Hz, NCH(HCH)O); 3.43-3.44 (2H, m, 
NCH2Ar); 3.96 (2H, d, J=4.9 Hz, OCH2CH=CH2); 5.15-5.28 (2H, m, CH=CH2); 5.81-5.96 (1H, 
m, CH=CH2); 7.30 (4H, s, CHarom). 13C NMR (68 MHz, CDCl3): δ 31.23 (NCH2CH); 38.56 
(NCH); 63.27 (NCH2Ar); 71.63 (OCH2CH=CH2); 72.18 (NCHCH2O); 116.62 (CH=CH2); 
128.25 and 129.20 (NCH2HCorthoHCmeta); 132.45 (CCl); 134.64 (CH=CH2); 137.63 (Carom,quat). 
IR (NaCl, cm-1): νmax = 1646, 1598, 1492, 1466, 1088, 807. MS (70 eV): m/z (%): 237/9 (M+, 2); 
180/2 (43);167 (24); 147 (35); 126 (14); 125/7 (100); 91 (56); 89 (22); 71 (10). Anal. Calcd for 
C13H16ClNO: C 65.68, H 6.78, N 5.89. Found: C 65.89, H 6.92, N 5.69. 
2-(tert-Butoxymethyl)-1-neopentylaziridine (5h). Yield 75%. Colorless oil. 1H NMR (CDCl3, 
60 MHz): δ 0.97 (9H, s, (CH3)3CCH2); 1.18 (9H, s, (CH3)3CO); 1.2-1.7 (3H, m, CH2CHN); 2.02 
and 2.31 (2H, 2×d, J=11.5 Hz, N(HCH)tBu); 3.0-3.7 (2H, m, OCH2). 13C NMR (CDCl3, 68 
MHz): δ 27.58 and 28.24 (2×(CH3)3C); 31.81 (CH2CHN); 32.61 ((CH3)3CCH2); 40.10 (CHN); 
64.70 (CH2O); 72.50 ((CH3)3CO); 73.67 (NCH2tBu). IR (NaCl, cm-1): νaz = 3040. MS (70 eV) 
m/z (%): 199 (M+, 1); 142 (7); 112 (26); 86 (100); 57 (59). Purity (GC) > 97%. Anal. Calcd for 
C12H25NO: C 72.31, H 12.64, N 7.03. Found: C 72.44, H 12.80, N 6.90. 
 
Synthesis of 2-(alkanoyloxymethyl)aziridines 7. General procedure 
To a solution of carboxylic acid (0.01 mol) in DMSO (15 mL) was added K2CO3 (2 equiv), and 
the resulting suspension was stirred for 30’ at room temperature. Subsequently, 2-
(bromomethyl)aziridine 3 (0.01 mol) was added, and the mixture was heated at 80°C for 15 
hours. The reaction mixture was poured into water (20 mL) and extracted with Et2O (3×15 mL). 
The combined organic extracts were washed with water (2×15 mL) and brine (20 mL). Drying 
(MgSO4), filtration of the drying agent and evaporation of the solvent afforded the corresponding 
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2-(alkanoyloxymethyl)aziridine 7, which was purified by filtration through silica gel 
(hexane/EtOAc 5/3). 
The spectral data of 1-(3-methylbenzyl)aziridin-2-ylmethyl 2-methylpropanoate 7a have been 
reported elsewhere.15
 
1-(2-Chlorobenzyl)aziridin-2-ylmethyl 2-methylpropanoate (7b). Yield 82%. Light-yellow 
oil. Filtration through silica gel (hexane/EtOAc 5/3). 1H NMR (300 MHz, CDCl3): δ 1.13 and 
1.15 (6H, 2×d, J=6.9 Hz, (CH3)2CH); 1.57 (1H, d, J=6.3 Hz, (HcisCH)N); 1.85 (1H, d, J=3.6 Hz, 
(HCHtrans)N); 1.88-1.95 (1H, m, NCH); 2.52 (1H, sept, J=7.0 Hz, (CH3)2)CH); 3.44 and 3.69 
(2H, 2×d, J=15.1 Hz, N(HCH)Ar); 3.85 and 4.27 (2H, 2×d×d, J=11.7, 7.6, 4.3 Hz, (HCH)O); 
7.17-7.35 and 7.67-7.69 (3H and 1H, 2×m, CHarom). 13C NMR (68 MHz, CDCl3): δ 18.90 and 
18.95 ((CH3)2)CH); 31.64 (NCH2CH); 33.90 ((CH3)2CH); 37.47 (CHN); 60.92 (NCH2Ar); 66.46 
(CH2O); 126.79, 128.08, 129.03 and 129.23 (HCarom); 132.88 (CCl); 136.71 (NCH2Carom,quat); 
176.84 (CO). IR (NaCl): νC=O = 1735 cm-1. MS (70 eV): m/z (%): 268/70 (M++1, 100). Anal. 
Calcd for C14H18ClNO2: C 62.80, H 6.78, N 5.23. Found: C 62.97, H 6.98, N 5.11. 
1-(4-Methylbenzyl)aziridin-2-ylmethyl 2-methylpropanoate (7c). Yield 86%. Light-yellow 
oil. Filtration through silica gel (hexane/EtOAc 5/3). 1H NMR (300 MHz, CDCl3): δ 1.10 and 
1.11 (6H, 2×d, J=7.0 Hz, (CH3)2CH); 1.51 (1H, d, J=6.3 Hz, (HcisCH)N); 1.77 (1H, d, J=3.6 Hz, 
(HCHtrans)N); 1.81-1.89 (1H, m, NCH); 2.33 (3H, s, CH3Ar); 2.46 (1H, sept, J=7.1 Hz, 
(CH3)2)CH); 3.26 and 3.56 (2H, 2×d, J=13.2 Hz, N(HCH)Ar); 3.80 and 4.19 (2H, 2×d×d, J=11.6, 
7.4, 4.7 Hz, (HCH)O); 7.12-7.30 (4H, m, CHarom). 13C NMR (68 MHz, CDCl3): δ 18.87 
((CH3)2)CH); 21.07 (CH3Ar); 31.65 (NCH2CH); 33.85 ((CH3)2CH); 37.12 (CHN); 64.03 
(NCH2Ar); 66.51 (CH2O); 128.07 and 129.02 (HCarom); 135.76 and 136.62 (2×Carom,quat); 177.02 
(CO). IR (NaCl): νC=O = 1735 cm-1. MS (70 eV): m/z (%): 248 (M++1, 100). Anal. Calcd for 
C15H21NO2: C 72.84, H 8.56, N 5.66. Found: C 72.97, H 8.71, N 5.59. 
1-Benzylaziridin-2-ylmethyl 2-methylbutyrate (7d). Mixture of diastereomers, ratio 53/47. 
Yield 77%. Light-yellow oil. Filtration through silica gel (hexane/EtOAc 5/3). 1H NMR (300 
MHz, CDCl3): δ 0.87 (3H, t, J=7.4 Hz, CH3CH2); 0.88 (3H, t, J=7.3 Hz, CH3CH2); 1.08 and 1.09 
(2×3H, 2×d, J=6.9 Hz, 2×CH3CH); 1.37-1.49 (2H, m, 2×(HCH)CH3); 1.52 (2H, d, J=6.6 Hz, 
2×(HcisCH)N); 1.57-1.74 (2H, m, 2×(HCH)CH3); 1.79 (2H, d, J=3.3 Hz, 2×(HCHtrans)N); 1.83-
1.90 (2H, m, 2×NCH); 2.25-2.44 (2H, m, 2×CHCH3); 3.32 and 3.58, 3.34 and 3.60 (2×2H, 
2×(2×d), J=13.5 Hz, 2×N(HCH)Ar); 3.83 (1H, d×d, J=11.6, 7.4 Hz, (HCH)O); 3.83 (1H, d×d, 
J=11.7, 7.3 Hz, (HCH)O); 4.11-4.31 (2H, m, 2×(HCH)O); 7.23-7.40 (5H, m, C6H5). 13C NMR 
(68 MHz, CDCl3): δ 11.59 (2×CH3CH2); 16.46 (2×CH3CH); 26.69 (2×CH3CH2); 31.65 
(2×NCH2CH); 37.28 and 37.33 (2×CHN); 40.92 (2×CHCH3); 64.29 (2×NCH2Ar); 66.45 
(2×CH2O); 127.09 (2×NCH2HCpara); 128.05 and 128.33 (2×NCH2HCorthoHCmeta); 138.94 
(2×Carom,quat); 176.38 (2×CO). IR (NaCl): νC=O = 1736 cm-1. MS (70 eV): m/z (%): 247 (M+, 3); 
219 (3); 146 (37); 91 (100); 85 (26); 72 (13); 57 (80). Anal. Calcd for C15H21NO2: C 72.84, H 
8.56, N 5.66. Found: C 73.03, H 8.76, N 5.58. 
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Synthesis of 2-[(1,2,4-triazol-1-yl)methyl]aziridines 8 and 2-[(imidazol-1-yl)methyl] 
aziridines 9. General procedure 
To a solution of 2-(bromomethyl)aziridine 3 (4.5 mmol) in acetonitrile (50 mL) was added 1,2,4-
triazole (5 equiv) and potassium carbonate (4 equiv). The resulting mixture was heated under 
reflux for 2.5 days, filtered and the solvent was removed in vacuo. A solution of sodium 
hydroxide (75 mL, 1N) was added to the residue, followed by extraction with diethyl ether (3×40 
mL). Drying (K2CO3), filtration of the drying agent and evaporation of the solvent afforded the 
corresponding 2-[(1,2,4-triazol-1-yl)methyl]aziridine 8, which was purified by column 
chromatography on silica gel (CHCl3/MeOH). 
1-Benzyl-2-[(1,2,4-triazol-1-yl)methyl]aziridine (8a). Yield 40%. Colorless oil. Rf = 0.13 
(CHCl3/MeOH 95/5). 1H NMR (CDCl3, 270 MHz): δ 1.63 (1H, d, J=6.3 Hz, N(HcisCH)CH); 
1.84 (1H, d, J=3.3 Hz, N(HCHtrans)CH); 2.01-2.09 (1H, m, CHN); 3.25 and 3.53 (2H, 2×d, 
J=12.9 Hz, N(HCH)Ar); 3.93 and 4.32 (2H, 2×d×d, J=14.2, 7.6, 4.3 Hz, NCH(HCH)N); 7.18-
7.36 (5H, m, C6H5); 7.85 and 7.92 (2×1H, 2×s, 2×N=CH). 13C NMR (CDCl3, 68 MHz): δ 32.61 
(CH2N); 37.65 (NCH); 52.60 (NCHCH2N); 64.10 (NCH2Ar); 126.84 (NCH2HCpara); 128.03 and 
128.48 (NCH2HCorthoHCmeta); 138.18 (Carom,quat); 143.07 and 151.61 (2×N=CH). IR (NaCl, cm-1): 
νC=N = 1658. MS (70 eV) m/z (%): no M+; 205 (20); 159 (15); 158 (19); 157 (11); 144 (19); 118 
(35); 106 (19); 105 (14); 91 (63); 89 (10); 80 (10); 79 (100); 78 (13); 77 (62); 71 (10); 65 (18); 
53 (15); 52 (10); 51 (32); 50 (15). Anal. Calcd for C12H14N4: C 67.27, H 6.59, N 26.15. Found: C 
67.41, H 6.83, N 26.03. 
1-[4-(Chlorophenyl)methyl]-2-[(1,2,4-triazol-1-yl)methyl]aziridine (8b). Yield 40%. 
Colorless oil. Rf = 0.15 (CHCl3/MeOH 97/3). 1H NMR (CDCl3, 270 MHz): δ 1.61 (1H, d, J=6.3 
Hz, N(HcisCH)CH); 1.85 (1H, d, J=3.3 Hz, N(HCHtrans)CH); 2.02-2.10 (1H, m, CHN); 3.27 and 
3.44 (2H, 2×d, J=13.2 Hz, N(HCH)Ar); 3.95 and 4.32 (2H, 2×d×d, J=14.4, 7.6, 4.0 Hz, 
NCH(HCH)N); 7.13 and 7.26 (2×2H, 2×d, J=8.4 Hz, 4×CHarom); 7.88 and 7.90 (2×1H, 2×s, 
2×N=CH). 13C NMR (CDCl3, 68 MHz): δ 33.23 (CH2N); 38.15 (NCH); 52.94 (NCHCH2N); 
63.74 (NCH2Ar); 128.97 and 129.67 (2×HCarom); 133.51 (CCl); 137.18 (NCH2Carom,quat); 143.54 
and 152.22 (2×N=CH). IR (NaCl, cm-1): νC=N = 1635. MS (70 eV) m/z (%): no M+; 180 (17); 
179 (19); 178 (19); 166/8 (37); 125/7 (100); 111 (13); 110 (12); 91 (10); 89 (24); 70 (12); 63 
(10); 55 (22), 54 (99). Anal. Calcd for C12H13ClN4: C 57.95, H 5.27, N 22.53. Found: C 58.12, H 
5.36, N 22.38. 
1-Benzyl-2-[(imidazol-1-yl)methyl]aziridine (9a). Yield 60%. Colorless oil. Rf = 0.26 
(CHCl3/MeOH 97/3). 1H NMR (CDCl3, 270 MHz): δ 1.56 (1H, d, J=6.3 Hz, N(HcisCH)CH); 
1.79 (1H, d, J=3.3 Hz, N(HCHtrans)CH); 1.82-1.90 (1H, m, CHN); 3.40 and 3.45 (2H, 2×d, 
J=12.9 Hz, N(HCH)Ar); 3.78 and 4.04 (2H, 2×d×d, J=14.4, 7.3, 4.1 Hz, NCH(HCH)N); 6.88 and 
7.01 (2×1H, 2×s, NCH=CH); 7.26-7.32 (5H, m, C6H5); 7.46 (1H, s, NHC=N). 13C NMR (CDCl3, 
68 MHz): δ 31.22 (CH2N); 37.81 (NCH); 48.84 (NCHCH2N); 63.11 (NCH2Ar); 118.19 
(HC=CH); 126.38 and 128.21 (NCH2HCpara and HC=CH); 127.19 and 127.57 
(NCH2HCorthoHCmeta); 136.08 (HC=N); 137.66 (Carom,quat). IR (NaCl, cm-1): νC=N = 1666. MS (70 
eV) m/z (%): no M+; 213 (19); 146 (10); 132 (63); 122 (17); 109 (17); 108 (10); 105 (26); 95 
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(15); 91 (100); 65 (14). Anal. Calcd for C13H15N3: C 73.21, H 7.09, N 19.70. Found: C 73.37, H 
7.25, N 19.58. 
1-[4-(Chlorophenyl)methyl]-2-[(imidazol-1-yl)methyl]aziridine (9b). Yield 75%. Colorless 
oil. Rf = 0.15 (CHCl3/MeOH 95/5). 1H NMR (CDCl3, 270 MHz): δ 1.54 (1H, d, J=6.3 Hz, 
N(HcisCH)CH); 1.79 (1H, d, J=3.3 Hz, N(HCHtrans)CH); 1.79-1.89 (1H, m, CHN); 3.33 and 3.42 
(2H, 2×d, J=13.4 Hz, N(HCH)Ar); 3.77 and 4.06 (2H, 2×d×d, J=14.4, 7.3, 4.1 Hz, 
NCH(HCH)N); 6.88 and 7.01 (2×1H, 2×s, NCH=CH); 7.19 and 7.28 (2×2H, 2×d, J=8.6 Hz, 
4×CHarom); 7.48 (1H, s, NHC=N). 13C NMR (CDCl3, 68 MHz): δ 31.72 (CH2N); 38.33 (NCH); 
49.17 (NCHCH2N); 62.66 (NCH2Ar); 118.51 (HC=CH); 127.96 and 128.84 
(NCH2HCorthoHCmeta); 128.57 (HC=CH); 132.29 (CCl); 136.53 (HC=N); 136.69 (Carom,quat). IR 
(NaCl, cm-1): νC=N = 1630. MS (70 eV) m/z (%): 247/9 (M+, 14); 148 (11); 125/7 (73); 109 (17); 
108 (15); 107 (13); 95 (16); 87 (11); 85 (67); 83 (100); 81 (10); 48 (12); 47 (27). Anal. Calcd for 
C13H14ClN3: C 63.03, H 5.70, N 16.96. Found: C 63.20, H 5.88, N 16.89. 
 
Synthesis of 2-(aminomethyl)aziridines 10. General procedure 
To an ice-cooled solution of a secondary amine (5 mmol) in dry diethyl ether or THF (5 mL) was 
added dropwise n-BuLi (2 mL, 1 equiv, 2.5M in hexane) via a syringe under nitrogen 
atmosphere. After stirring for 1 hour at 0°C, a solution of 2-(bromomethyl)aziridine 3 (1 equiv) 
in Et2O or THF (5 mL) was added via a syringe at 0°C. The resulting solution was further stirred 
at room temperature for 18-20 hours under nitrogen atmosphere. Workup was carried out by 
pouring the reaction mixture in an aqueous sodium hydroxide solution (10 mL, 0.5M), followed 
by extraction with diethyl ether (2×10 mL, 1×5 mL). After drying of the organic phase with 
K2CO3 and filtration of the drying agent, the solvent was removed in vacuo, affording the desired 
2-(aminomethyl)aziridine 10. 
The spectral data of 2-(aminomethyl)aziridines 10a,b,d have been reported elsewhere.20,4d 
 
1-(2-Methylpropyl)-2-(N,N-diethylaminomethyl)aziridine (10c). Yield 92%. Light-yellow oil. 
1H NMR (500 MHz, CDCl3): δ 0.89 and 0.93 (6H, 2×d, J=6.7 Hz, CH(CH3)2); 1.05 (6H, t, J=7.2 
Hz, 2×CH2CH3); 1.25 (1H, d, J=6.3 Hz, N(HcisCH)CH); 1.48 (1H, m, CHN); 1.55 (1H, d, J=3.4 
Hz, N(HCHtrans)CH); 1.80 (1H, sept, J=6.7 Hz, CH(CH3)2); 1.95 and 2.15 (2H, 2×d×d, J=11.6, 
7.3, 6.3 Hz, N(HCH)CHMe2); 2.42 and 2.58 (2H, 2×d×d, J=13.3, 5.8, 5.7 Hz, NCH(HCH)N); 
2.60-2.70 (4H, m, 2×CH2CH3). 13C NMR (68 MHz, CDCl3): δ 11.7 (2×CH2CH3); 20.9 and 21.0 
(CH(CH3)2); 29.2 (CH(CH3)2); 33.5 (NCH2CHCH2NEt2); 37.8 (NCH2CHCH2NEt2); 47.3 
(2×CH2CH3); 56.4 (CH2NEt2); 69.6 (NCH2CHMe2). IR (NaCl, cm-1): ν = 3035, 1469, 1383, 
1070. MS (70 eV) m/z (%): 184 (M+, 5); 169 (2); 155 (2); 141 (2); 113 (16); 112 (39); 86 (100); 
72 (39); 70 (70); 58 (16); 56 (23). Anal. Calcd for C11H24N2: C 71.68, H 13.12, N 15.20. Found: 
C 71.84, H 13.29, N 15.11. 
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Synthesis of 2-[(alkylsulfanyl)methyl]aziridines 11. General procedure 
To a solution of sodium methoxide (2 equiv) in methanol (0.25N) was added an alkanethiol (3 
equiv) at room temperature. After stirring for 30 minutes, aziridine 3 (2 mmol) was added, and 
the resulting mixture was further stirred for 8 hours at room temperature. The reaction mixture 
was poured into water (50 mL) and extracted with CH2Cl2 (3×30 mL). The combined organic 
extracts were washed with water (2×15 mL) and brine (20 mL). Drying (MgSO4), filtration of 
the drying agent and evaporation of the solvent afforded the corresponding 2-
[(alkylsulfanyl)methyl]aziridines 11, which were purified by column chromatography on silica 
gel (Hexane/EtOAc 4/1). 
 
1-[(4-Chlorophenyl)methyl]-2-[(isopropylsulfanyl)methyl]aziridine (11a). Yield 84%. 
Colorless oil. Rf = 0.25 (Hexane/EtOAc 4/1). 1H NMR (CDCl3, 270 MHz): δ 1.22 and 1.24 (6H, 
2×d, J=6.5 Hz, 2×CH3); 1.47 (1H, d, J=5.9 Hz, N(HcisCH)CH); 1.72-1.74 (2H, m, CHN and 
N(HCHtrans)CH); 2.52 and 2.65 (2H, 2×d×d, J=13.4, 5.9, 5.6 Hz, (HCH)S); 2.92 (1H, sept, J=6.5 
Hz, CHMe2); 3.38 and 3.44 (2H, 2×d, J=13.5 Hz, N(HCH)Ar); 7.30 (4H, s, CHarom). 13C NMR 
(CDCl3, 68 MHz): δ 23.32 and 23.41 (2×CH3); 33.60 (CH2S); 34.09 (NCH2CH); 34.64 
(CHMe2); 39.71 (NCH); 63.74 (NCH2Ar); 128.41 and 129.43 (NCH2HCorthoHCmeta); 132.76 
(CCl); 137.45 (Carom,quat). IR (NaCl, cm-1): νmax = 1597, 1491, 1462, 1240, 805. MS (70 eV) m/z 
(%): 255/7 (M+, 1); 181 (49); 180/2 (75); 166 (19); 146 (18); 125/7 (100); 99/101 (8): 89 (25); 56 
(20). Anal. Calcd for C13H18ClNS: C 61.04, H 7.09, N 5.48. Found: C 61.18, H 7.25, N 5.32. 
2-[(Allylsulfanyl)methyl]-1-[(4-chlorophenyl)methyl]aziridine (11b). Yield 60%. Colorless 
oil. Rf = 0.33 (Hexane/EtOAc 4/1). 1H NMR (CDCl3, 270 MHz): δ 1.46 (1H, d, J=6.2 Hz, 
N(HcisCH)CH); 1.72-1.73 (2H, m, CHN and N(HCHtrans)CH); 2.46 and 2.57 (2H, 2×d×d, J=13.5, 
5.6, 5.6 Hz, NCH(HCH)S); 3.12 (2H, d, J=7.2 Hz, SCH2CH=CH2); 3.38 and 3.43 (2H, 2×d, 
J=13.3 Hz, N(HCH)Ar); 5.03-5.08 (2H, m, CH=CH2); 5.68-5.81 (1H, m, CH=CH2); 7.30 (4H, s, 
CHarom). 13C NMR (CDCl3, 68 MHz): δ 33.55 (NCHCH2S); 34.03 (NCH2CH); 34.72 
(SCH2CH=CH2); 39.35 (NCH); 63.74 (NCH2Ar); 117.16 (CH=CH2); 128.44 and 129.43 
(NCH2HCorthoHCmeta); 132.79 (CCl); 134.19 (CH=CH2); 137.41 (Carom,quat). IR (NaCl, cm-1): νmax 
= 1634, 1597, 1491, 1464, 805. MS (70 eV) m/z (%): 253/5 (M+, 3); 183 (34); 181 (61); 180/2 
(85); 166 (38); 154 (27); 146 (34); 125/7 (100); 99/101 (24); 89 (38); 56 (28). Anal. Calcd for 
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